1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6E3A44EE5D0E9D71D85257AC3006E7C12
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/wp-ultimate-business-model-planning-thousand-year-future?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RC




Products & Services

White Paper - The Ultimate Business Model: Planning that Thousand Year Future

ID: WP-45


Pages: 6


Published: Pre-2013


Delivery Format: Online


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Download White Paper

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
Heightened regulatory scrutiny coupled with economic unrest has many biopharmaceutical executives focused on cutting costs and reorganizing key functions to serve physicians, payers, patients, and stakeholders more efficiently. However, two thought leaders recently stepped away from the micro point of view of operating in today’s business landscape to draft “the thousand-year business model” for a modern biopharmaceutical company.

Christopher Bogan, chief executive officer of Best Practices, LLC, and Daniel Pascheles, Ph.D., vice president at Merck & Co., Inc., jointly-authored the white paper titled “The Ultimate Business Model: Planning that Thousand Year Future.” The full text is published in the August 2012 issue of Pharmaceutical Executive, a leading trade journal for the pharmaceutical industry.

>>To read the entire article, click Add to Cart on the right and proceed through the download process.

Aside from proven tactics for business survival, including partnerships (see M&A Integration Excellence), technology investments (see Deploying the iPad to Sales & Managed Markets Teams), and talent management, the white paper covered twelve potential paths or opportunity fronts to reinvention for the hypothetical BioPharmaCo., referenced throughout the piece.

These opportunity fronts spanned the organization, from the frontline to senior management, from finance to legal, from market research to supply chain. The twelve potential paths for reinvention highlighted directly improving patient care in areas such as health outcome services (see HOLs: The New Payer Facilitator) and treatment adherence services (see Zithromax: Case Study in Successful Re-Launch), in addition to several others mentioned in the white paper.

Drawing from themes in nature, such as procreation, pollination, gene mutations, and environmental pressures, Bogan and Pascheles emphasized adaptability as a critical factor for survival, both in the natural and business worlds.

“In an era where success is monitored and measured in microseconds, planning for the long-term is increasingly seen as an abstract absurdity,” the white paper reads. “Yet the principles of natural selection, when applied to business, suggest that a lasting business model is still possible – if you learn to adapt.”

Industries Profiled:
Consulting; Biotech; Medical Device; Pharmaceutical; Diagnostic; Clinical Research


Companies Profiled:
Pharma; Biotech; Medical Device Companies